MedTrace Logo

A Study of Human Substance Balance and Biotransformation of [14C]SHR0302

NCT05047341 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-07-01

No results posted yet for this study

Summary

The study is being conducted to evaluate the absorption, metabolism and excretion of \[14C\]SHR0302 in healthy Chinese adult male subjects.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

DRUG

SHR0302、[14C]SHR0302

8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2021-09-19
Completion
2022-06-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047341 on ClinicalTrials.gov